Adults with primary primary appendiceal adenocarcinoma face a higher risk of developing a second primary cancer, including ...

Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced ...

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor ...

Emily King of Mobile, Alabama, was diagnosed with colon cancer five years ago at the age of 27. She had experienced some diarrhea, abdominal pain and anemia, but having cancer had never entered ...

Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and chemotherapy improved progression-free survival but did not achieve ...

The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...

By studying biomarkers known to be involved in gastrointestinal cancers, researchers have developed a biomarker algorithm that, when combined with a noninvasive method to collect esophageal cells for ...

An editor in his early 40s thought the tiny numb spot on his nose was innocuous. A year and six doctors later, he learned it ...

By studying biomarkers known to be involved in gastrointestinal cancers, researchers at the Johns Hopkins Kimmel Cancer ...

Inhibrx (INBX) announced preliminary efficacy and safety data from the Phase 1 trial of ozekibart in combination with Folfiri for the treatment ...

Here are the most anticipated abstracts to keep an eye on going into the 2025 ASCO Gastrointestinal Cancers Symposium.